Virtual screening and lab experiments identified CBD as a selective inhibitor of phosphodiesterase 9 (PDE9), an enzyme implicated in neurodegeneration, with nanomolar-range potency confirmed in vitro.
Neuroscience researchers, pharmacologists, drug development scientists studying neurodegeneration.
CBD inhibited brain enzyme PDE9 at nanomolar concentrations in vitro
What the researchers found
Computational screening of 7 phytocannabinoids and 4 terpenes identified CBD as a potential PDE9 ligand with a calculated binding energy of -9.1 kcal/mol and stable molecular dynamics interaction. In vitro PDE9 inhibition assay confirmed CBD inhibits the enzyme in the nanomolar range.
Why it matters
PDE9 inhibitors are being studied as potential treatments for Alzheimer disease and other neurodegenerative conditions. If CBD acts partly through PDE9 inhibition, this could explain some of its reported neuroprotective effects and open a new avenue for drug development.
The numbers in context
Binding energy: -9.1 kcal/mol. CBD inhibited PDE9 in the nanomolar range in vitro. 7 phytocannabinoids and 4 terpenes screened.
How the study worked
Combined ligand-based and structure-based virtual screening (docking and molecular dynamics simulations) followed by in vitro PDE9 enzymatic inhibition assay. Screened 7 phytocannabinoids and 4 terpenes.
What this study cannot tell us
In vitro enzymatic assay does not confirm in vivo relevance. Nanomolar potency in a cell-free system may not translate to effective brain concentrations. CBD has many proposed molecular targets, and PDE9 may be one of many. No animal or human data yet.
How to read the evidence
Computational screening validated by in vitro enzymatic assay. Preliminary evidence requiring in vivo confirmation.
When this study was published
Published in 2023.
The bigger picture
CBD has shown neuroprotective effects in various studies, but the mechanisms remain unclear. Identifying PDE9 as a specific molecular target adds a concrete mechanism to what has been a vague body of evidence about CBD and brain health.
Questions still open
- Does CBD reach brain concentrations sufficient for PDE9 inhibition at typical doses?
- Would CBD-based PDE9 inhibition show benefits in animal models of neurodegeneration?
Common questions
How might CBD protect the brain?
Is this evidence that CBD treats Alzheimer disease?
Read the original research
Virtual screening and in vitro experiments highlight cannabidiol as a drug-like phosphodiesterase 9 inhibitor.
The European journal of neuroscience, 57(12), 1954-1965
Citation
Ribaudo, Giovanni; Landucci, Elisa; Giannangeli, Matteo; Mazzantini, Costanza; Maccarinelli, Giuseppina; Mastinu, Andrea; Bonini, Sara Anna; Memo, Maurizio; Pellegrini-Giampietro, Domenico E; Gianoncelli, Alessandra. (2023). Virtual screening and in vitro experiments highlight cannabidiol as a drug-like phosphodiesterase 9 inhibitor.. The European journal of neuroscience, 57(12), 1954-1965. https://doi.org/10.1111/ejn.15869
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk